Table 4 Factors influencing KRAS testing in non-metastatic CRC patients
From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer
KRAS testing N = 255/979 (26.1%) | Univariate analysis P-Value | Multivariate analysis | |||
|---|---|---|---|---|---|
Odds ratio | 95% CI | P-Value | |||
Age (years) | 0.0004 | < 0.0001 | |||
> 75 | 90 / 446 (20.2%) | 1 | Ref | ||
60–75 | 123 / 382 (32.2%) | 2.69 | 1.83–3.95 | ||
< 60 | 42 / 151 (27.8%) | 2.26 | 1.34–3.81 | ||
Sex | 0.25 | 0.15 | |||
Women | 133 / 541 (24.6%) | 1 | Ref | ||
Men | 122 / 438 (27.9%) | 0.77 | 0.55–1.09 | ||
Site of the primary tumour | 0.010 | 0.026 | |||
Rectum | 47 / 245 (19.2%) | 1 | Ref | ||
Right colon | 105 / 347 (30.3%) | 1.95 | 1.20–3.16 | ||
Left colon | 103 / 387 (26.6%) | 1.47 | 0.92–2.35 | ||
TNM stage | < 0.0001 | < 0.0001 | |||
I | 21 / 219 (9.6%) | 1 | Ref | ||
II | 100 / 380 (26.3%) | 5.24 | 2.98–9.21 | ||
III | 134 / 380 (35.3%) | 9.62 | 5.47–16.90 | ||
Tumour grade (MD = 133) | 0.0082a | ||||
Well | 114 / 347 (32.8%) | – | – | – | |
Moderate | 103 / 445 (23.2%) | ||||
Poor | 17 / 54 (31.5%) | ||||
Geographical area of primary treatment (MD = 2) | < 0.0001 | < 0.0001 | |||
Charente-Maritime | 63 / 305 (20.7%) | 1 | Ref | ||
Charente | 13 / 173 (7.5%) | 0.19 | 0.10–0.37 | ||
Deux-Sèvres | 75 / 182 (41.2%) | 3.74 | 2.35–5.95 | ||
Vienne | 94 / 222 (42.3%) | 3.24 | 1.95–5.39 | ||
Outside the region | 10 / 95 (10.5%) | 0.36 | 0.16–0.79 | ||
Status of the center (MD = 2) | < 0.0001 | < 0.0001 | |||
Public Hospital | 77 / 408 (18.9%) | 1 | Ref | ||
Private hospital | 149 / 429 (34.7%) | 4.18 | 2.74–6.37 | ||
University hospital | 29 / 140 (20.7%) | 0.88 | 0.44–1.75 | ||